- PREPARATION OF HYDRATED POLYMORPHS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALT
-
The present technology provides methods of making anhydrous crystalline Form II and monohydrate crystalline Form S of the lactic acid salt of 4-amino-5-fluoro-3-(6-{4-mefhyipiperazin- 1 -yl)-l H-benzimidazol-2-yl)-1H-quinoiin-2-one.
- -
-
Page/Page column 15
(2011/10/13)
-
- CRYSTALLINE FORMS AND TWO SOLVATED FORMS OF 4-AMINO-5-FLUORO-3-[5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]QUINOLIN-2(1H)-ONE LACTIC ACID SALTS
-
[0057] Crystalline forms or polymorphs of 4-amino-5-fIuoro-3-[5-(4-methylpiperazin-1- yl)-1H-benzimidazol-2-yl]quinoIin-2(1 H)-one lactic acid salts, as well as to methods of making the same, pharmaceutical compositions comprising the same and methods of treatment using the same.
- -
-
Page/Page column 8
(2009/10/22)
-
- TREATMENT OF MELANOMA
-
Methods of treating melanoma include administering a compound of Structure (I), a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The comp
- -
-
-
- Formulation of Quinolinones
-
A pharmaceutical formulation, comprising: a compound of formula (I), a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof and at least one ingredient selected from the group consisting of (i) cellulose; (ii) sil
- -
-
-
- CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE LACTIC ACID SALTS
-
The present invention relates to non-hydrate crystalline forms of 4-amino- 5-fluoro-3 -[6-(4-methylpiperazin- 1 -yl)- 1 H-benzimidazol-2-yl] - 1 H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-arnino-5-fiuoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts.
- -
-
Page/Page column 25
(2008/06/13)
-
- METHODS FOR TREATING DRUG RESISTANT CANCER
-
A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comp
- -
-
-
- TREATMENT OF METASTASIZED TUMORS
-
Methods of treating metastatic cancer such as metastasized tumors include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mix
- -
-
Page/Page column 46-48
(2008/06/13)
-
- METHODS FOR SYNTHESIZING HETEROCYCLIC COMPOUNDS
-
A method for synthesizing a heterocyclic compound includes: reacting 1-methylpiperazine with 5-chloro-2-nitroaniline at an internal temperature sufficient to provide a compound of Formula VIH The 1-methylpiperazine and the 5-chloro-2-nitroaniline are reac
- -
-
Page/Page column 72-73
(2008/06/13)
-
- MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES
-
Methods of using compounds having Structure (I) or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.
- -
-
-